Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.

Authors

Michael Lübbert, Pierre W Wijermans, Michal Kicinski, Sylvain Chantepie, Walter J F M Van der Velden, Richard Noppeney, Laimonas Griškevičius, Andreas Neubauer, Martina Crysandt, Radovan Vrhovac, Mario Luppi, Stephan Fuhrmann, Ernesta Audisio, Anna Candoni, Olivier Legrand, Robin Foà, Gianluca Gaidano, Danielle van Lammeren-Venema, Eduardus F M Posthuma, Mels Hoogendoorn, Anne Giraut, Stephanie Antunes, Marian Stevens-Kroef, Joop H Jansen, Aniek O de Graaf, Fabio Efficace, Emanuele Ammatuna, Quentin Levesque, Ralph Wäsch, Heiko Becker, Nicole Blijlevens, Ulrich Dührsen, Frédéric Baron, Stefan Suciu, Adriano Venditti, Gerwin Huls, EORTC Leukemia Group, Italian Group for Adult Hematologic Diseases, and German MDS Study Group

Published in

Blood neoplasia. Volume 3. Issue 3. Pages 100246. Epub May 13, 2026.

PMID:
42436879
Bibliographic data and abstract were imported from PubMed on 12 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.